Transcriptomic analysis of long noncoding RNAs and mRNAs expression profiles in the spinal cord of bone cancer pain

Xinran Hou1, Yingqi Weng1, Qulian Guo1

  • 1Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.

Molecular Brain
|March 27, 2020
PubMed

Insights

This study reveals long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) are altered in bone cancer pain (BCP). These findings offer new therapeutic targets for managing chronic pain associated with cancer.

Area of Science:

  • Molecular Biology
  • Neuroscience
  • Oncology

Background:

  • Bone cancer pain (BCP) is a prevalent form of chronic cancer pain with incompletely understood mechanisms.
  • Long non-coding RNAs (lncRNAs) are emerging as significant players in pain research, but their role in BCP remains unexplored.

Purpose of the Study:

  • To investigate the differential expression profiles of lncRNAs and mRNAs in the spinal cord of a rat model of BCP.
  • To identify potential regulatory networks and therapeutic targets for BCP.

Main Methods:

  • Establishment of a rat model of BCP via Walker 256 carcinoma cell implantation.
  • Transcriptome sequencing of the lumbar spinal cord to analyze lncRNA and mRNA expression.
  • Validation of differentially expressed genes (DEGs) using RT-qPCR.
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.
  • Construction of co-expression and competing endogenous RNA (ceRNA) networks.

Main Results:

  • Identification of 1220 differentially expressed mRNAs (DEmRNAs) and 323 differentially expressed lncRNAs (DElncRNAs) in the BCP model.
  • Validation of 10 DEmRNAs and 10 DElncRNAs.
  • GO and KEGG analyses indicated enrichment in inflammatory and immunologic pathways.
  • Construction of regulatory networks highlighting potential lncRNA-mediated gene regulation.

Conclusions:

  • This study provides a comprehensive landscape of lncRNA and mRNA dysregulation in the spinal cord associated with BCP.
  • Identified DElncRNAs and DEmRNAs represent potential therapeutic targets for future BCP treatments.